The progress in Alzheimer's cannot possibly have gone unnoticed by anyone in the industry. Especially not in Sweden, as Swedish BioArctic are pioneers in the field. In November, the company's drug Leqembi (lecanemab) received a nod from the European Medicines Agency's scientific committee CHMP.
But Leqembi has not yet been formally approved in Eur...
Life science trends 2025 – Neurology
New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver active substances across the blood-brain barrier are being developed. In addition, a new type of drug for MS is making its debut. This part of trend insights on life science 2025 is about neurology.
Life Science Sweden's editor-in-chief Samuel Lagercrantz writes about trends in life science for 2025. Today: neurology. Photo: Adam Boman/ Colourbox
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration